Evidence map›Paper›PMID 33317630›Full record

ArticleMobile DNA2020

SeqURE - a new copy-capture based method for sequencing of unknown Retroposition events.

Alexander Y Komkov, Shamil Z Urazbakhtin, Maria V Saliutina, Ekaterina A Komech, Yuri A Shelygin, Gaiaz A Nugmanov, Vitaliy P Shubin, Anastasia O Smirnova, Mikhail Y Bobrov, Alexey S Tsukanov and 4 more

Open access · goldAbstract read
In one paragraph

Article in Mobile DNA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Alexander Y KomkovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia. alexandrkomkov@yandex.ru.ORCID http://orcid.org/0000-0001-9113-698X
Shamil Z UrazbakhtinShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
Maria V SaliutinaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
Ekaterina A KomechShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
Yuri A ShelyginRyzhikh National Medical Research Centre for Coloproctology of the Ministry of Health of Russia, Moscow, Russia.
Gaiaz A NugmanovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
Vitaliy P ShubinRyzhikh National Medical Research Centre for Coloproctology of the Ministry of Health of Russia, Moscow, Russia.
Anastasia O SmirnovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
Mikhail Y BobrovV.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia.
Alexey S TsukanovRyzhikh National Medical Research Centre for Coloproctology of the Ministry of Health of Russia, Moscow, Russia.
Anastasia V SnezhkinaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
Anna V KudryavtsevaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
Yuri B LebedevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
Ilgar Z MamedovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia. imamedov@mx.ibch.ru.
Institute of Bioorganic Chemistry · RUState Scientific Center of Coloproctology · RUEngelhardt Institute of Molecular Biology · RUCentral European Institute of Technology · CZNational Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Healthcare of the Russian Federation · RU

Funding

Russian Science Foundation 18-14-00244
6 · The paper itself

Abstract

backgroundRetroelements (REs) occupy a significant part of all eukaryotic genomes including humans. The majority of retroelements in the human genome are inactive and unable to retrotranspose. Dozens of active copies are repressed in most normal tissues by various cellular mechanisms. These copies can become active in normal germline and brain tissues or in cancer, leading to new retroposition events. The consequences of such events and their role in normal cell functioning and carcinogenesis are not yet fully understood. If new insertions occur in a small portion of cells they can be found only with the use of specific methods based on RE enrichment and high-throughput sequencing. The downside of the high sensitivity of such methods is the presence of various artifacts imitating real insertions, which in many cases cannot be validated due to lack of the initial template DNA. For this reason, adequate assessment of rare (< 1%) subclonal cancer specific RE insertions is complicated.

resultsHere we describe a new copy-capture technique which we implemented in a method called SeqURE for Sequencing Unknown of Retroposition Events that allows for efficient and reliable identification of new genomic RE insertions. The method is based on the capture of copies of target molecules (copy-capture), selective amplification and sequencing of genomic regions adjacent to active RE insertions from both sides. Importantly, the template genomic DNA remains intact and can be used for validation experiments. In addition, we applied a novel system for testing method sensitivity and precisely showed the ability of the developed method to reliably detect insertions present in 1 out of 100 cells and a substantial portion of insertions present in 1 out of 1000 cells. Using advantages of the method we showed the absence of somatic Alu insertions in colorectal cancer samples bearing tumor-specific L1HS insertions.

conclusionsThis study presents the first description and implementation of the copy-capture technique and provides the first methodological basis for the quantitative assessment of RE insertions present in a small portion of cells.

Indexed as

Copy captureHigh-throughput sequencingHuman genomeInsertional polymorphismRetroelements

Identifiers

PMID33317630
PMCPMC7734759
OpenAlexW3113366874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.